Navigation Links
ROXRO Announces FDA Accepts for Review NDA for ROX-888 for the Management of Acute Moderate to Severe Pain
Date:2/6/2009

MENLO PARK, Calif., Feb. 6 /PRNewswire/ -- ROXRO announced today that the U.S. Food and Drug Administration (FDA) has accepted for review the New Drug Application (NDA) for its lead investigational prescription drug candidate, ROX-888, for the management of acute moderate to severe pain. ROX-888 is an intranasal formulation of ketorolac, a non-steroidal anti-inflammatory drug (NSAID), designed to provide ambulatory patients with a convenient, potent, and fast-acting option for acute pain relief, without the risk of addiction or the other negative effects of narcotics. The NDA package for ROX-888 includes data from more than 1,000 subjects and 14 clinical trials. If approved, ROX-888 is expected to be the first non-narcotic intranasal analgesic indicated for the management of acute moderate to severe pain.

(Photo: http://www.newscom.com/cgi-bin/prnh/20090206/AQF506)

"This milestone for ROX-888 is a significant business accomplishment for ROXRO. Our virtual operating structure has enabled us to develop an extensive NDA package for our lead product candidate in an extremely capital-efficient manner," said Roberto Rosenkranz, Chief Executive Officer of ROXRO. "We believe that ROX-888 has the potential to fill important needs in the large and growing market for acute moderate to severe pain treatments. Currently approved forms of ketorolac are already well accepted by the physician community for in-hospital use, and we believe physicians will quickly adopt this investigational intranasal form of ketorolac as a new therapeutic option to replace or minimize oral opioid use for take-home prescriptions. As we plan a potential product launch at the end of 2009, pending FDA approval, we are now seeking a commercialization partner to help us realize the full benefit of this drug."

ROX-888 has been tested in four contro
'/>"/>

SOURCE ROXRO PHARMA, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine news :

1. ROXRO PHARMA Marks 5th Year Of Cafe Scientifique Sponsorship
2. Nu Skin Enterprises Announces 5 Percent Increase in Quarterly Dividend
3. Kmart Announces Voluntary Recall of Certain Items Containing Peanuts Sold at Super Kmart Bakery Locations
4. ReBuilder Medical Technologies, Inc. (RBRM) Announces Sales Increase In Jan. 09
5. ResMed Inc Announces Record Financial Results for the Quarter and Six Months Ended December 31, 2008
6. United American Healthcare Corporation Announces Fiscal 2009 Second Quarter Results
7. Medical Device Consultants, Inc. (MDCI) Announces Senior Staff Changes and Promotions
8. Medical Device Consultants, Inc. (MDCI) Announces Clinical Services Staff Promotions
9. CVS/pharmacy Announces Plans for New Distribution Center in Southern New York
10. Transition Therapeutics Announces Completion of Patient Enrolment of Phase 2 Study of TT-223 in Type 2 Diabetes Patients
11. ATS Medical Announces Australian Regulatory Approval for ATS 3f Aortic Bioprosthesis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... (PRWEB) May 25, 2013 Dr. Leslie ... non-invasive procedure FDA-approved to lift skin on the neck, on ... at her practice, Medical Aesthetics. , Ultherapy is a non-surgical ... own natural healing process to lift the skin over time. ... first time, to see and then treat the deepest support ...
(Date:5/25/2013)... York (PRWEB) May 25, 2013 Life ... which are used to detect and create a new ... test reading and are also known as biotechnology reagents. ... bioscience, diagnosis and education. , This market is driven ... reagents in the field of therapeutics, growth in research ...
(Date:5/25/2013)... Idaho (PRWEB) May 25, 2013 A ... prevalent type of peripheral neuropathy. According to neuropathy expert ... , it is estimated that the disorder affects almost ... common complication arising from Diabetes. The high blood sugar ... Diabetes and patients suffering from it usually tend to ...
(Date:5/25/2013)... viruses and parasites that affect both dogs and humans, ... than can result in liver or kidney failure -- ... veterinarian. These germs could be found in ... Susan Nelson, a clinical associate professor at Kansas State ... can be fatal, even with treatment," she said in ...
(Date:5/25/2013)... The report “Global Food Encapsulation Market ... Ingredients, Shell Materials, Packaging, & Geography: Trends & ... market with analysis and forecasting of the global ... driving and restraining factors for the global food ... challenges. The market is segmented and revenue are ...
Breaking Medicine News(10 mins):Health News:Dr. Leslie Gerstman Is Now Offering the Non-surgical Facelifting Procedure – Ultherapy – in NYC and NJ 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 2Health News:Life Sciences And Analytical Reagents Market - New Industry Research Report is Now Available for Pre-Order at Transparency Market Research 3Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Hidden Dangers Dog Dog Parks 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 2Health News:Food Encapsulation Market to Reach $42 Billion by 2016 - New Report by MarketsandMarkets 3
... in the human diet mean people today are more at ... said.Researchers at the University of Newcastle believe that changes to ... off its anti-cancer agents. ,The researchers are working ... in fighting stomach cancer. They are carrying out two trials ...
... an amino-acid taste receptor.Dr Charles S. Zuker, from ... of California, San Diego, reports his team's findings ... tastes — bitter, salty, sour, sweet, and umami. ... (MSG).Receptors that responded to umami have been discovered ...
... are associated with permutation in brain structure that appear ... conducted by researchers at the University of Iowa.// ... and 54 male control subjects, the researchers used magnetic ... They found that the volume of the anterior portion ...
... shun most of the dangers of developing lung cancer. There are ... are former smokers compared with those who continue to smoke.// Over ... lung cancer in the world. ,One of the authors ... study in 1950 established the smoking and lung cancer link. A ...
... pollutant emitted by power plants and vehicles raises the ... of dying from lung cancer or heart disease//, and ... authors contend that simply living in a major urban ... its way into your lungs when you breathe, increasing ...
... exercise cut the risk of diabetes by over half. ... be at increased risk of developing diabetes.// Given that ... very useful if there was some way of helping ... for the Diabetes Prevention Programme in the US have ...
Cached Medicine News:Health News:Comprehension of taste receptor, 2
(Date:5/24/2013)... CITY, England and BOSTON ... leading GPCR drug discovery and development company, is pleased to announce ... as a Consultant to augment the Company,s business development capabilities in ... Mr Usui has more than 15 years of experience in business ... roles at Perlegen Sciences, Inc., Roche Pharma ( Japan ...
(Date:5/23/2013)... , May 23, 2013  Vanda Pharmaceuticals Inc. (Vanda) ... has been named the 2013 Life Science Firm of the ... (TCM).  Vanda was honored at the TCM,s 25 th ... , Maryland.  The Tech Awards Celebration recognizes the leaders ... Maryland and the surrounding regions. ...
(Date:5/23/2013)... DIEGO , May 23, 2013 Neurocrine Biosciences, ... Kevin Gorman , President and Chief Executive Officer ... 38 th Annual dbAccess Health Care Conference in Boston.   ... May 30 at 11:20 a.m. Eastern Time / 8:20 a.m. ... accessed on the Company,s website at http://www.neurocrine.com . ...
Breaking Medicine Technology:Heptares Augments Business Development Capabilities in Japan and Other Asian Territories 2Vanda Pharmaceuticals Named the 2013 Life Science Firm of the Year by the Tech Council of Maryland 2
... 2010 Arlington Medical Resources (AMR), a provider ... diagnostic imaging industries, finds that, in the treatment ... use of vitamin K antagonists, as a class, ... oral formulation, overall low cost and widespread inclusion ...
... 2010 DSM Pharmaceutical Products, the custom manufacturing ... license agreement with c-LEcta GmbH for proprietary screening ... to c-LEcta,s proprietary alcohol dehydrogenases for enzyme screening ... manufacturing of pharmaceutical active ingredients and intermediates. Germany-based ...
Cached Medicine Technology:Use of Vitamin K Antagonists in the Treatment of Atrial Fibrillation is Driven by the Availability of an Oral Formulation, Cost and Widespread Inclusion on Guidelines and Formularies 2DSM Expands Industrial Biocatalysis Platform With c-LEcta Agreement 2DSM Expands Industrial Biocatalysis Platform With c-LEcta Agreement 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: